Drug Trial Radar · NCT02795676
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Jun 2016
Primary completion
Oct 2021
Study completion Jul 2022
Sponsor
- Lead sponsor
- ProtalixIndustry
- Sponsor type
- Industry
- Collaborators
- Chiesi Farmaceutici S.p.A.
- First posted
- Jun 10, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a randomized, double-blind, active control study of the enzyme replacement therapy (ERT) drug PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function. Patients who had been treated for approximately 1 year with agalsidase beta and who had been on a stable dose of that product for at least 6 months were randomized in a 2:1 ratio to either switch to PRX-102 or to continue treatment with agalsidase beta. Both treatments were delivered by intravenous infusions every two weeks, at a dosage of 1 mg/kg.
Conditions
- Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa)Biological
PRX-102 1 mg/kg every 2 weeks
agalsidase betaBiological
agalsidase beta 1 mg/kg every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR)Time frame: 24 months
Locations
29 sites in 12 countries. Site status is shown where the registry gives one.
UAB Medicine
Birmingham, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
University of California Irvine Center
Orange, California
University of California San Diego
San Diego, California
Emory University School of Medicine
Atlanta, Georgia
University of Iowa Hosptials and Clinics
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
Infusion Associates
Grand Rapids, Michigan
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Institute of Metabolic Disease, Baylor Healthcare
Dallas, Texas
Renal Disease Research Institute, LLC - Dallas
Dallas, Texas
Eccles Primary Children's Outpatient Services Building
Salt Lake City, Utah
O+O Alpan LLC
Fairfax, Virginia
Medical College of Wisconsin
Milwaukee, Wisconsin
Vseobecna fakultni nemocnice v Praze
Prague, Czech Republic, Czechia
Turku University Central Hospital
Turku, Finland
Hôpital Raymond Poincaré
Paris, France
Semmelweis Egyetem
Budapest, Hungary
Azienda Ospedaliera Universitaria "Federico II"
Naples, Italy
Academisch Medisch Centrum
Amsterdam, Netherlands
Haukeland University Hospital Klinisk Forskningspost
Bergen, Norway
General Hospital Slovenj Gradec
Slovenj Gradec, Slovenia
Hospital de Dia Quiron Zaragoza
Zaragoza, Spain
Klinik und Poliklinik für Innere Medizin UniversitätsSpital Zürich
Zurich, Switzerland
Addenbrooke's Hospital
Cambridge, United Kingdom
The Royal Free Hospital
London, United Kingdom
Salford Royal NHS Foundation Trust
Salford, United Kingdom
Institute of Metabolism and Systems Research
Edgbaston, Birmingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.